Clinical Trial Update: I-125 Versus Pd-103 for Medium Risk Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing I-125 brachytherapy versus Pd-103 brachytherapy for medium-risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• I-125 brachytherapy source (Iodine-125)
• Pd-103 brachytherapy source (Palladium-103)

Snippet

Sponsor: VA Puget Sound Health Care System | Conditions: Prostate Cancer | Phase 3 | Status: UNKNOWN